Rogaratinib

Drug Profile

Rogaratinib

Alternative Names: BAY-1163877

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Breast cancer

Most Recent Events

  • 28 Oct 2017 Interim adverse events, efficacy and pharmacokinetic data from a phase I trial in solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
  • 08 Sep 2017 Interim adverse events and efficacy data from a phase I trial in Solid tumours presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 08 Sep 2017 Updated efficacy data from a phase I trial in Solid tumours presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top